These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11329844)

  • 1. Bayesian value-of-information analysis. An application to a policy model of Alzheimer's disease.
    Claxton K; Neumann PJ; Araki S; Weinstein MC
    Int J Technol Assess Health Care; 2001; 17(1):38-55. PubMed ID: 11329844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of a cost-utility model of donepezil for Alzheimer's disease.
    Peters JL; Anderson R; Hoyle M; Hyde C
    Int J Technol Assess Health Care; 2013 Apr; 29(2):147-54. PubMed ID: 23514698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AD2000: donepezil in Alzheimer's disease.
    Schneider LS
    Lancet; 2004 Jun; 363(9427):2100-1. PubMed ID: 15220027
    [No Abstract]   [Full Text] [Related]  

  • 4. Economic evaluation of donepezil treatment for Alzheimer's disease in Japan.
    Ikeda S; Yamada Y; Ikegami N
    Dement Geriatr Cogn Disord; 2002; 13(1):33-9. PubMed ID: 11731713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation.
    Getsios D; Blume S; Ishak KJ; Maclaine GD
    Pharmacoeconomics; 2010; 28(5):411-27. PubMed ID: 20402542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of donepezil in moderate to severe Alzheimer disease.
    van Hout HP; Bosmans JE; Stalman WA
    Neurology; 2005 Apr; 64(7):1320; author reply 1320. PubMed ID: 15824386
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil.
    Stewart A; Phillips R; Dempsey G
    Int J Geriatr Psychiatry; 1998 Jul; 13(7):445-53. PubMed ID: 9695032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan.
    Fuh JL; Wang SJ
    Int J Geriatr Psychiatry; 2008 Jan; 23(1):73-8. PubMed ID: 17520661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First International Pharmacoeconomic Conference on Alzheimer's Disease: report and summary.
    Whitehouse PJ; Winblad B; Shostak D; Bhattacharjya A; Brod M; Brodaty H; Dor A; Feldman H; Forette F; Gauthier S; Hay J; Henke C; Hill S; Mastey V; Neumann P; O'Brien B; Pugner K; Sano M; Sawada T; Stone R; Wimo A
    Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):266-80. PubMed ID: 9876955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease.
    Teipel SJ; Ewers M; Reisig V; Schweikert B; Hampel H; Happich M
    Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):330-6. PubMed ID: 17404699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donepezil. Pharmacoeconomic implications of therapy.
    Foster RH; Plosker GL
    Pharmacoeconomics; 1999 Jul; 16(1):99-114. PubMed ID: 10539126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An economic evaluation of donepezil in the treatment of Alzheimer's disease.
    Small GW; Donohue JA; Brooks RL
    Clin Ther; 1998; 20(4):838-50. PubMed ID: 9737841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Equity in the new NHS: hard lessons from implementing a local healthcare policy on donepezil.
    Doyle Y
    BMJ; 2001 Jul; 323(7306):222-4. PubMed ID: 11473920
    [No Abstract]   [Full Text] [Related]  

  • 14. Randomized clinical trial results for donepezil in Alzheimer's disease: is the treatment glass half full or half empty?
    Farlow MR
    J Am Geriatr Soc; 2008 Aug; 56(8):1566-7. PubMed ID: 18808602
    [No Abstract]   [Full Text] [Related]  

  • 15. Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications.
    Fagnani F; Lafuma A; Pechevis M; Rigaud AS; Traykov L; Seux ML; Forette F
    Dement Geriatr Cogn Disord; 2004; 17(1-2):5-13. PubMed ID: 14560059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom.
    Getsios D; Blume S; Ishak KJ; Maclaine G; Hernández L
    Alzheimers Dement; 2012 Jan; 8(1):22-30. PubMed ID: 21420366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic testing in combination with preventive donepezil treatment for patients with amnestic mild cognitive impairment: an exploratory economic evaluation of personalized medicine.
    Djalalov S; Yong J; Beca J; Black S; Saposnik G; Musa Z; Siminovitch K; Moretti M; Hoch JS
    Mol Diagn Ther; 2012 Dec; 16(6):389-99. PubMed ID: 23188525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Delaying Alzheimer dementia. Patient and family relieved--costs lowered].
    MMW Fortschr Med; 2000 Aug; 142(33-34):56-7. PubMed ID: 10998909
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of donepezil therapy on health costs in a Medicare managed care plan.
    Hill JW; Futterman R; Mastey V; Fillit H
    Manag Care Interface; 2002 Mar; 15(3):63-70. PubMed ID: 11925682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relief for caregivers. Anti-dementia drug saves costs].
    MMW Fortschr Med; 2001 Oct; 143(42):64. PubMed ID: 11697297
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.